Healthcare
Insight Molecular Diagnostics Inc.(IMDX)
Live Price
Offline$5.61
+3.31% today
1Y Change
+61.92%
Window
Jun 25, 2025 โ Jun 22, 2026
- Market Cap
- $110.00M
- Revenue Growth
- +115.6%
- EPS Growth
- +64.6%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Insight Molecular Diagnostics Inc. (IMDX) is a Healthcare stock with a market cap of $110.00M and listed on NASDAQ. The stock last traded around $5.61 and up 61.9% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of +115.6%, EPS growth of +64.6%, a dividend yield of 0.0%. What stands out right now is revenue +115.6%, EPS +64.6%, free cash flow -19.5% with operating margin -754.1% and ROIC -197.4%. Valuation already assumes a fairly strong business story at price/sales 26.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines IMDX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+115.6% vs +7.6% peer median
Operating Margin
Below sector median
-754.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +115.6% and EPS at +64.6%, with operating margin around -754.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +6.4% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | +1.4% | +29.3% | +19.1% |
2026 Mar 26, 2026 | -13.7% | -13.4% | -8.5% | -8.5% |
2025 Nov 10, 2025 | -41.7% | +10.7% | -1.5% | -24.3% |
Benchmark Edge
IMDX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IMDX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IMDX Max Drawdown
-69.93%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IMDX and SPY.
Company Overview
Insight Molecular Diagnostics Inc.
NASDAQ Capital Market
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
- Leadership
- Joshua Riggs
- IPO Date
- Dec 30, 2015
- Employees
- 46
- Street Address
- 15 Cushing
- Mailing
- Nashville, TN, 92618
- Region
- Nashville, TN, US
- Reporting Currency
- USD
- Investor Line
- 949 409 7600
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 26.5
- Price/Book
- โ
Growth
- Revenue
- +115.6%
- EPS
- +64.6%
- Free Cash Flow
- -19.5%
Profitability
- Gross Margin
- 4.7%
- Operating Margin
- -754.1%
- Net Margin
- -1238.5%
- ROE
- 684.6%
- ROIC
- -197.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 1.27
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.